ALK-Abelló (ALK) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
26 Oct, 2026Opening remarks and agenda
AGM legally convened with 99% of votes and share capital represented.
Agenda covered activity reports, annual report approval, profit allocation, remuneration, Board elections, auditor appointment and other business.
Financial performance review
Revenue rose 15% in local currencies to over DKK 5.5 billion, with an EBIT margin of 20%.
Operating profit exceeded DKK 1.1 billion, a record, driven by tablet sales and cost control.
Operating cash flow was DKK 1.2 billion; tablet sales grew 24%.
2025 guidance: 9–13% revenue growth and an EBIT margin of ~25%.
Board and executive committee updates
The Board held 13 meetings and several committee sessions, focusing on the new strategy and self-evaluation.
Anders Hedegaard was re-elected Chair, Lene Skole Vice Chair, and Gitte Aabo, Lars Holmqvist, Jesper Høiland, Bertil Lindmark and Alan Main as directors.
Management remuneration increased with performance; total Board remuneration was DKK 41 million.
Latest events from ALK-Abelló
- No ordinary dividend; Alan Main joined the Board as governance measures were approved.ALK
AGM 2022 - Governance proposals passed; directors were re-elected and no ordinary dividend was declared.ALK
AGM 2024 - 2022 accounts approved, Board refreshed, and no ordinary dividend declared.ALK
AGM 2023 - 15% revenue growth and 65% EBIT increase, with strong outlook and major product launches ahead.ALK
Q4 2024 - Q2 2026 saw 18% revenue and 19% EBIT growth, with upgraded full-year outlook.ALK
Q2 2026 - 18% revenue and 19% EBIT growth in Q2, with upgraded full-year outlook and strong tablet sales.ALK
Q2 2026 - 2025 growth, a DKK 355 million dividend and approved governance changes.ALK
AGM 2026 - Q3 revenue up 18% and EBIT margin at 23%, driven by tablet and JextⓇ sales, with neffyⓇ deal fueling growth.ALK
Q3 2024 - Q1 saw 12% revenue growth, 50% EBIT surge, and strong pediatric and neffy® product momentum.ALK
Q1 2025